Modeling the interactions between osteoblast and osteoclast activities in bone remodeling

被引:340
作者
Lemaire, V
Tobin, FL
Greller, LD
Cho, CR
Suva, LJ
机构
[1] GlaxoSmithKline, Sci Comp & Math Modeling, King Of Prussia, PA USA
[2] GlaxoSmithKline, Bone & Cartilage Biol, King Of Prussia, PA USA
关键词
mathematical modeling; bone cells; osteoporosis; therapeutic strategies; differentiation; parathyroid hormone;
D O I
10.1016/j.jtbi.2004.03.023
中图分类号
Q [生物科学];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
We propose a mathematical model explaining the interactions between osteoblasts and osteoclasts, two cell types specialized in the maintenance of the bone integrity. Bone is a dynamic, living tissue whose structure and shape continuously evolves during life. It has the ability to change architecture by removal of old bone and replacement with newly formed bone in a localized process called remodeling. The model described here is based on the idea that the relative proportions of immature and mature osteoblasts control the degree of osteoclastic activity. In addition, osteoclasts control osteoblasts differentially depending on their stage of differentiation. Despite the tremendous complexity of the bone regulatory system and its fragmentary understanding, we obtain surprisingly good correlations between the model simulations and the experimental observations extracted from the literature. The model results corroborate all behaviors of the bone remodeling system that we have simulated, including the tight coupling between osteoblasts and osteoclasts, the catabolic effect induced by continuous administration of PTH, the catabolic action of RANKL, as well as its reversal by soluble antagonist OPG. The model is also able to simulate metabolic bone diseases such as estrogen deficiency. vitamin D deficiency, senescence and glucocorticoid excess. Conversely, possible routes for therapeutic interventions are tested and evaluated. Our model confirms that anti-resorptive therapies are unable to partially restore bone loss, whereas bone formation therapies yield better results. The model enables us to determine and evaluate potential therapies based on their efficacy. In particular, the model predicts that combinations of anti-resorptive and anabolic therapies provide significant benefits compared with monotherapy, especially for certain type of skeletal disease. Finally, the model clearly indicates that increasing the size of the pool of preosteoblasts is an essential ingredient for the therapeutic manipulation of bone formation. This model was conceived as the first step in a bone turnover modeling platform. These initial modeling results are extremely encouraging and lead us to proceed with additional explorations into bone turnover and skeletal remodeling. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 309
页数:17
相关论文
共 96 条
[1]
PROSTAGLANDIN-E2 PREVENTS BONE LOSS AND ADDS EXTRA BONE TO IMMOBILIZED DISTAL FEMORAL METAPHYSIS IN FEMALE RATS [J].
AKAMINE, T ;
JEE, WSS ;
KE, HZ ;
LI, XJ ;
LIN, BY .
BONE, 1992, 13 (01) :11-22
[2]
TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation [J].
Alliston, T ;
Choy, L ;
Ducy, P ;
Karsenty, G ;
Derynck, R .
EMBO JOURNAL, 2001, 20 (09) :2254-2272
[3]
Aubin J E, 2000, Medscape Womens Health, V5, P5
[4]
Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO
[5]
2-L
[6]
Advances in the osteoblast lineage [J].
Aubin, JE .
BIOCHEMISTRY AND CELL BIOLOGY, 1998, 76 (06) :899-910
[7]
Hindlimb unloading in rat decreases preosteoblast proliferation assessed in vivo with BrdU incorporation [J].
Barou, O ;
Palle, S ;
Vico, L ;
Alexandre, C ;
Lafage-Proust, ML .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 274 (01) :E108-E114
[8]
Steroid hormone receptor expression and action in bone [J].
Bland, R .
CLINICAL SCIENCE, 2000, 98 (02) :217-240
[9]
ROLE OF ACTIVE AND LATENT TRANSFORMING GROWTH-FACTOR-BETA IN BONE-FORMATION [J].
BONEWALD, LF ;
DALLAS, SL .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 55 (03) :350-357
[10]
Boyce BF, 1999, LAB INVEST, V79, P83